Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
January 31, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
January 30, 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Prefilled Syringes Market revenue to surpass USD 45 Billion by 2033, says Research Nester
January 25, 2024 05:00 ET
|
Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global prefilled syringes market size is projected to expand at ~13% CAGR between 2023 and 2033.The market is expected to garner a revenue of USD 45...
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
January 08, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024 09:30 ET
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023 07:09 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
November 30, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Study: Brain Training Improves Cognitive Function In Multiple Sclerosis
November 06, 2023 07:59 ET
|
Posit Science
SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- A study conducted at the University of Nebraska Medical Center showed use of a commercially-available brain training app significantly improved...
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
November 01, 2023 08:07 ET
|
ZyVersa Therapeutics
NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.